About Us

Learn more about InSitu Biologics

Overview

InSitu Biologics

InSitu Biologics, LLC is an emerging biotech company focusing on development of new and proprietary treatments using its Matrix™ BioHydrogel. Their lead product, AnestaGel™, is a long-lasting and long-acting non-opiate painkiller, targeted for use in peri-operative regional pain management.

Contact

For Media & Press

Please contact

Katie M.
Katie@insitubiologics.com

For Investors

Please contact

Jim Segermark, CEO
Jim@insitubiologics.com
651-337-4799

Pre-Clinical Results

As compared to EXPAREL (Pacira, Inc.), the industry leading post-operative pain treatment.

300% Longer

Initial animal study revealed AnestaGel™ lasted up to 300% longer

8x More Capacity

AnestaGel™ carried 8 times more payload

72+ Hours

AnestaGel™ had full nerve block beyond 72 hours

See our study at the Journal of Pain Research
  • AnestaGel™

    • A Non-Opioid Surgical Analgesic

    InSitu Biologics is an emerging drug delivery company focusing on development of new and proprietary treatments using its Matrix™ BioHydrogel. Their lead product, AnestaGel™, is a long-lasting and long-acting non-opiate painkiller, targeted for use in peri-operative regional pain management.

    • 22+ US Patents Issued, with matching OUS positions
    • Hydrogel technology licensed from Cleveland Clinic Foundation
    • Tunable, biocompatible, and pH neutral platform
    • High dose drug-load reservoir capacity with a predictable pharmacological effect
    • Non-opioid pain relief option

    Investment Opportunity

    InSitu Biologics intends to launch a Regulation A+ offering to a limited number of investors.

    Why Invest

    • Non-opioid painkiller – pre-clinical stage
    • Lasts up to 300% longer than leading competitor*
    • 22 U.S. Patents
    • Invest with your IRA

    The Offering

    Pre-Valuation
    $24,035,753
    Max Raise
    $10,000,000
    Min. Per Investor
    $287.50
    Current Share Price
    $6.85

    Competitor Market Size

    Learn More About Investing

    Timeline

    • 2016

      Q1
      Filed additional patent(s)

      Q2
      White Paper published

      Q3
      Completed maximum dosing study with no toxicity

      Q4
      Presented at PODD-Boston

    • 2017

      Q1
      Completed first GLP study

      Q2
      Proved more pain relief compared to Exparel in pre-clinical study

      Q3
      GLP publication accepted

      Q4
      Raised over $400k

    • 2018

      Q1
      Completed Financial Audit
      Converted all debt
      Filed $10,000,000 RegA+ Offering

      Q2
      Launch RegA+ Offering
      Announce GLP Paper by Hutchins & Taylor

      Q3
      Begin Phase 1 program manufacturing

      Q4
      Announce final GLP Study results

    • 2019

      Q1
      Expect approval for Phase 1 Clinical Study of AnestaGel

      Q2
      Clinical Trials

      Q3
      Clinical Trials

      Q4
      TBD

    Team

    James Segermark

    CEO

    Bill Taylor

    Chief Scientist

    Daniel Sipple

    DO Medical Advisor

    Jacob Hutchins

    MD Medical Advisor

    Get in Touch

    For media or investor inquires please contact
    Contact Us